(GERN) Geron - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.121m USD | Total Return: 28.5% in 12m

Cancer Drugs, Therapeutics
Total Rating 32
Safety 29
Buy Signal -1.09
Biotechnology
Industry Rotation: -3.7
Market Cap: 1.12B
Avg Turnover: 28.7M USD
ATR: 6.56%
Peers RS (IBD): 39.3
Risk 5d forecast
Volatility70.7%
Rel. Tail Risk-9.74%
Reward TTM
Sharpe Ratio0.54
Alpha1.07
Character TTM
Beta0.736
Beta Downside2.517
Drawdowns 3y
Max DD78.98%
CAGR/Max DD-0.08
EPS (Earnings per Share) EPS (Earnings per Share) of GERN over the last years for every Quarter: "2021-03": -0.09, "2021-06": -0.09, "2021-09": -0.08, "2021-12": -0.1, "2022-03": -0.09, "2022-06": -0.07, "2022-09": -0.1, "2022-12": -0.1, "2023-03": -0.07, "2023-06": -0.09, "2023-09": -0.08, "2023-12": -0.09, "2024-03": -0.09, "2024-06": -0.1, "2024-09": -0.04, "2024-12": -0.0356, "2025-03": -0.03, "2025-06": -0.02, "2025-09": -0.03, "2025-12": -0.0212, "2026-03": 0,
EPS CAGR: 32.73%
EPS Trend: 83.3%
Last SUE: 1.89
Qual. Beats: 1
Revenue Revenue of GERN over the last years for every Quarter: 2021-03: 0.137, 2021-06: 0.107, 2021-09: 0.109, 2021-12: 1.04, 2022-03: 0.123, 2022-06: 0.073, 2022-09: 0.297, 2022-12: 0.103, 2023-03: 0.021, 2023-06: 0.029, 2023-09: 0.164, 2023-12: 0.023, 2024-03: 0.304, 2024-06: 0.882, 2024-09: 28.271, 2024-12: 47.537, 2025-03: 39.603, 2025-06: 49.036, 2025-09: 47.227, 2025-12: 48.015, 2026-03: null,
Rev. CAGR: 390.97%
Rev. Trend: 84.3%
Last SUE: -0.44
Qual. Beats: 0

Warnings

Interest Coverage Ratio -1.6 is critical

Altman Z'' -12.17 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: GERN Geron

Geron Corporation (NASDAQ: GERN) is a commercial-stage biopharmaceutical company specializing in oncology therapeutics.

Their primary product is RYTELO, a telomerase inhibitor. This drug treats myelodysplastic syndromes (MDS) in adult patients who have low- to intermediate-1 risk and transfusion-dependent anemia. MDS is a group of cancers where immature blood cells in the bone marrow do not mature or become healthy blood cells.

The company, founded in 1990, operates from Foster City, California. The biotechnology sector is characterized by extensive research and development cycles and significant regulatory hurdles for product approval.

For more in-depth analysis of Gerons financials and market position, consider exploring ValueRay.

Headlines to Watch Out For
  • RYTELO sales performance drives revenue growth
  • Myelodysplastic syndromes market competition impacts share
  • Clinical trial results for pipeline candidates affect valuation
  • Regulatory approvals for new indications expand market
  • Manufacturing costs and supply chain efficiency influence profitability
Piotroski VR‑10 (Strict) 1.5
Net Income: -85.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.19 > 0.02 and ΔFCF/TA 17.46 > 1.0
NWC/Revenue: 222.3% < 20% (prev 523.0%; Δ -300.7% < -1%)
CFO/TA -0.19 > 3% & CFO -111.0m > Net Income -85.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.66 > 1.5 & < 3
Outstanding Shares: last quarter (667.2m) vs 12m ago 3.27% < -2%
Gross Margin: 85.96% > 18% (prev 0.98%; Δ 8.50k% > 0.5%)
Asset Turnover: 31.59% > 50% (prev 12.97%; Δ 18.62% > 0%)
Interest Coverage Ratio: -1.63 > 6 (EBITDA TTM -52.1m / Interest Expense TTM 32.7m)
Altman Z'' -12.17
A: 0.72 (Total Current Assets 520.3m - Total Current Liabilities 111.5m) / Total Assets 570.5m
B: -3.25 (Retained Earnings -1.86b / Total Assets 570.5m)
C: -0.09 (EBIT TTM -53.1m / Avg Total Assets 582.2m)
D: -5.38 (Book Value of Equity -1.85b / Total Liabilities 344.7m)
Altman-Z'' Score: -12.17 = D
Beneish M -2.62
DSRI: 0.42 (Receivables 39.2m/38.8m, Revenue 183.9m/77.0m)
GMI: 1.14 (GM 85.96% / 98.01%)
AQI: 0.52 (AQ_t 0.09 / AQ_t-1 0.17)
SGI: 2.39 (Revenue 183.9m / 77.0m)
TATA: 0.04 (NI -85.8m - CFO -111.0m) / TA 570.5m)
Beneish M-Score: -2.62 (Cap -4..+1) = A
What is the price of GERN shares? As of April 11, 2026, the stock is trading at USD 1.67 with a total of 16,567,642 shares traded.
Over the past week, the price has changed by -4.57%, over one month by +2.45%, over three months by +16.78% and over the past year by +28.46%.
Is GERN a buy, sell or hold? Geron has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy GERN.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the GERN price?
Analysts Target Price 3.4 103.6%
Geron (GERN) - Fundamental Data Overview as of 08 April 2026
P/S = 6.0961
P/B = 4.7217
P/EG = -2.38
Revenue TTM = 183.9m USD
EBIT TTM = -53.1m USD
EBITDA TTM = -52.1m USD
Long Term Debt = 119.5m USD (from longTermDebt, last quarter)
Short Term Debt = 19.4m USD (from shortTermDebt, last quarter)
Debt = 251.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -108.2m USD (recalculated: Debt 251.6m - CCE 359.8m)
Enterprise Value = 1.01b USD (1.12b + Debt 251.6m - CCE 359.8m)
Interest Coverage Ratio = -1.63 (Ebit TTM -53.1m / Interest Expense TTM 32.7m)
EV/FCF = -9.11x (Enterprise Value 1.01b / FCF TTM -111.1m)
FCF Yield = -10.97% (FCF TTM -111.1m / Enterprise Value 1.01b)
FCF Margin = -60.43% (FCF TTM -111.1m / Revenue TTM 183.9m)
Net Margin = -46.65% (Net Income TTM -85.8m / Revenue TTM 183.9m)
Gross Margin = 85.96% ((Revenue TTM 183.9m - Cost of Revenue TTM 25.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 53.18%)
Tobins Q-Ratio = 1.78 (Enterprise Value 1.01b / Total Assets 570.5m)
Interest Expense / Debt = 2.90% (Interest Expense 7.30m / Debt 251.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -42.0m (EBIT -53.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.66 (Total Current Assets 520.3m / Total Current Liabilities 111.5m)
Debt / Equity = 1.11 (Debt 251.6m / totalStockholderEquity, last quarter 225.9m)
 Debt / EBITDA = 2.08 (negative EBITDA) (Net Debt -108.2m / EBITDA -52.1m)
 Debt / FCF = 0.97 (negative FCF - burning cash) (Net Debt -108.2m / FCF TTM -111.1m)
 Total Stockholder Equity = 250.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.74% (Net Income -85.8m / Total Assets 570.5m)
RoE = -34.23% (Net Income TTM -85.8m / Total Stockholder Equity 250.6m)
RoCE = -14.35% (EBIT -53.1m / Capital Employed (Equity 250.6m + L.T.Debt 119.5m))
 RoIC = -11.35% (negative operating profit) (NOPAT -42.0m / Invested Capital 369.7m)
 WACC = 7.42% (E(1.12b)/V(1.37b) * Re(8.57%) + D(251.6m)/V(1.37b) * Rd(2.90%) * (1-Tc(0.21)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
 [DCF] Fair Price = unknown (Cash Flow -111.1m)
 EPS Correlation: 83.34 | EPS CAGR: 32.73% | SUE: 1.89 | # QB: 1
Revenue Correlation: 84.34 | Revenue CAGR: 391.0% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.02 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+80.6% | Growth Revenue=+24.7%
EPS next Year (2027-12-31): EPS=0.08 | Chg7d=-0.015 | Chg30d=-0.015 | Revisions Net=-1 | Growth EPS=+500.0% | Growth Revenue=+44.1%
External Resources
Dataroma Stockcircle